The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and ...

Shares of Tectonic Therapeutic Inc. (NASDAQ:TECX) closed Jan. 30 at $54.84, up $29.12, or 113%, on what Leerink analyst David ...

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara ...

Montelukast does not appear to increase the risk for neuropsychiatric adverse events in children and adolescents, according to a study published in JAMA Pediatrics. Montelukast is a leukotriene ...

Tectonic Therapeutic shares doubled, to $56.80, after the company said it saw positive interim data from a Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, ...

Women aged 18 to 45 years with IBD were invited to complete a survey regarding knowledge, attitude, and beliefs about contraception.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Despite contraceptives being available in public clinics, the Gauteng Department of Health is concerned by increasing teenage pregnancies.

An international lineup of the world’s leading healthcare start-ups competed in the final of the Innov8 competition ...

The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S.

Tectonic Therapeutic (TECX) announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, ...